Posted on 12/8/17
Merk 2018 Outlook
With the stock market and Bitcoin reaching all-time highs, what can possibly go wrong? In offering my thoughts on 2018, I see my role in reminding . . .
Posted on 12/8/17
Why 2017 Was a Year to Forget for Merck & Co. Inc.
Better luck next year. That's what Merck & Co. (NYSE:MRK) is hoping for after a disappointing 2017. Merck stock is down year to date by 7%, . . .
Posted on 12/8/17
Merck To Lay Off 58 Employees In Charlotte
Merck Sharpe & Dohme Corp., a subsidiary of Merck & Co., will close one of its Charlotte facilities, resulting in 58 lost jobs, according to a . . .
Posted on 12/7/17
Marquis Health Services Announces Partnership with Reliant Rehabilitation
Marquis Health Services’ therapy gyms offer professional services and state-of-the-art equipment. At The Brentwood Rehabilitation and Healthcare Center in Danvers, Mass., the program includes a smart . . .
Posted on 12/6/17
Tabula Rasa HealthCare Prices Sale of Shares of Common Stock
MOORESTOWN, N.J., Dec. 05, 2017 (GLOBE NEWSWIRE) -- Tabula Rasa HealthCare, Inc. (NASDAQ:TRHC), a healthcare technology company optimizing medication safety by deploying new medication risk mitigation . . .
Posted on 12/5/17
Will 2018 Be Johnson & Johnson's Best Year Yet?
There are still several weeks left in the year, but Johnson & Johnson (NYSE:JNJ) appears to be on course to generate its second-highest stock performance over . . .
Posted on 12/5/17
3 Reasons Pfizer Should Buy Celgene in 2018
You might think it's a crazy idea. Maybe it is a crazy idea. But sometimes crazy ideas are the ones that wind up being the best. . . .
Posted on 12/5/17
Tabula Rasa HealthCare Announces Proposed Offering of Common Stock
MOORESTOWN, N.J., Dec. 04, 2017 (GLOBE NEWSWIRE) -- Tabula Rasa HealthCare, Inc. (NASDAQ:TRHC) , a healthcare technology optimizing medication safety by deploying new medication risk mitigation . . .
Posted on 12/5/17
OncLive and The Ruesch Center Honored the 2017 Winners of the Luminary Awards in GI Cancers
CRANBURY, N.J.--(BUSINESS WIRE)--The inaugural Luminary Awards in GI Cancer, which was hosted by OncLive®andThe Ruesch Center for the Cure of Gastrointestinal Cancers on Friday, Dec 1., . . .
Posted on 12/5/17
Sunspire Health Launches New Website
LYNDHURST, N.J.--(BUSINESS WIRE)--Sunspire Health, a nationwide network of addiction treatment facilities offering personalized treatment and addiction recovery services across the United States, announced today the launch . . .
Posted on 12/4/17
Blue Oak and PsychoGenics Announce a Drug Discovery Partnership
BOSTON & PARAMUS, N.J.--(BUSINESS WIRE)--Blue Oak Pharmaceuticals, Inc. (Blue Oak) and PGI Drug Discovery LLC (PsychoGenics), today announced that they have entered into a partnership to . . .
Posted on 12/1/17
Celgene (CELG) Presents at Evercore ISI Biopharma Catalyst/Deep Dive Conference (Transcript)
Celgene Corp. (NASDAQ:CELG)Evercore ISI Biopharma Catalyst/Deep Dive ConferenceNovember 30, 2017 11:00 AM ETExecutivesScott Smith - President and COOPatrick Flanigan - Corporate Vice PresidentAnalystsUnidentified Company RepresentativeWe have . . .
Posted on 12/1/17
Celgene Is Oversold, Buy And Keep Until At Least 2020
Celgene (NASDAQ:CELG) was a popular investment earlier this year, reaching a high of $147.17 on October 2, 2017, corresponding to a market capitalization of $116 billion. . . .
Posted on 12/1/17
Blavatnik's Stake Could Intensify Teva's Hemorrhaging
Billionaire investor Len BlavatnikTeva (TEVA) has been reeling from a $40 billion acquisition of Allergan's (AGN) generics business in 2015 that has since gone awry. Generic . . .
Posted on 12/1/17
Better Buy: GlaxoSmithKline plc vs. Pfizer
Big drug companies can add an element of stability to investor portfolios. People get sick and need treatment whether the economy is booming or tanking. And . . .
Posted on 12/1/17
Will Johnson & Johnson Do a Stock Split in 2018?
Healthcare has been an exciting industry lately, and Johnson & Johnson (NYSE:JNJ) casts a wide net over the sector. The company not only sells well-known consumer . . .
Posted on 12/1/17
Better Buy: Ziopharm Oncology Inc. vs. Celldex Therapeutics, Inc.
The American Cancer Society expects 600,920 Americans to die from cancer this year, but Ziopharm Oncology Inc. (NASDAQ:ZIOP) and Celldex Therapeutics, Inc. (NASDAQ:CLDX) aim to lower . . .
Posted on 11/30/17
It's A Good Time To Buy Merck
Best Reward-to-Risk trade-off of the DJ-30 stocksThat accolade today goes to Merck & Co., Inc. (MRK).Figure 1(Used with permission)Upside price rewards come from the behavioral analysis . . .
Posted on 11/30/17
Recordati Rare Diseases Partners With the National Urea Cycle Disorders Foundation
Recordati Rare Diseases Inc., a biopharmaceutical company committed to providing orphan therapies to underserved rare disease communities in the U.S., today announced a new Check Ammonia . . .
Posted on 11/29/17
Ortho Clinical Diagnostics Recognized with Global Business Excellence Award
Ortho Clinical Diagnostics (Ortho), a global leader of in vitro diagnostics, today announced that it has received a Global Business Excellence Award for Ortho's VITROS® NEPHROCHECK™ . . .
Posted on 11/27/17
Teva Layoffs Will Bring More Pain To An Already Fragile Company
Things are about to get worse for Teva (TEVA). Instead of the company offering up good news to its investors it has set the stage for . . .
Posted on 11/21/17
Pfizer Inc. 2017 Q3 - Results - Earnings Call Slides
The following slide deck was published by Pfizer Inc. in conjunction with their 2017 Q3 earnings call. 111READ FULL ARTICLE HERE
Posted on 11/21/17
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on November 15, 2017 it approved non-statutory stock options to purchase an aggregate of 61,500 shares of its . . .
Posted on 11/21/17
Recro Pharma Secures $100 Million Credit Facility
MALVERN, Pa., Nov. 20, 2017 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (Nasdaq:REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for hospital and other acute . . .
Posted on 11/20/17
Why Fitch Sacked Teva
I previously wondered who would downgrade Teva Pharmaceutical (NYSE:TEVA) first - Moody's or S&P? Monday Fitch beat them to it, downgrading the generics giant to junk . . .

